These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37182352)

  • 1. Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.
    Adams A; Blawatt S; MacDonald S; Finnick R; Lajeunesse J; Harrison S; Byres D; Schechter MT; Oviedo-Joekes E
    Int J Drug Policy; 2023 Jul; 117():104058. PubMed ID: 37182352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.
    Adams A; Blawatt S; Magel T; MacDonald S; Lajeunesse J; Harrison S; Byres D; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):56. PubMed ID: 37777766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 4. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
    Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
    Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.
    Treitler PC; Bowden CF; Lloyd J; Enich M; Nyaku AN; Crystal S
    J Subst Abuse Treat; 2022 Jan; 132():108514. PubMed ID: 34098210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
    López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
    J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.
    Oviedo-Joekes E; Dobischok S; Carvajal J; MacDonald S; McDermid C; Klakowicz P; Harrison S; LaJeunesse J; Chow N; Brown M; Gill S; Schechter M
    BMC Health Serv Res; 2023 May; 23(1):553. PubMed ID: 37237256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
    Jaffe K; Blawatt S; Lehal E; Lock K; Easterbrook A; MacDonald S; Harrison S; Lajeunesse J; Byres D; Schechter M; Oviedo-Joekes E
    Harm Reduct J; 2023 Apr; 20(1):51. PubMed ID: 37060027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
    Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
    J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy.
    Krawczyk N; Rivera BD; Levin E; Dooling BCE
    Lancet Public Health; 2023 Mar; 8(3):e238-e246. PubMed ID: 36841564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
    Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
    Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
    Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
    Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternity care during COVID-19: a qualitative evidence synthesis of women's and maternity care providers' views and experiences.
    Flaherty SJ; Delaney H; Matvienko-Sikar K; Smith V
    BMC Pregnancy Childbirth; 2022 May; 22(1):438. PubMed ID: 35619069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences and needs of front-line nurses during the COVID-19 pandemic: A systematic review and qualitative meta-synthesis.
    Ding S; Deng S; Zhang Y; Wang Q; Liu Z; Huang J; Yang X
    Front Public Health; 2022; 10():805631. PubMed ID: 35937273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
    Darnton JB; Bhatraju EP; Beima-Sofie K; Michaels A; Hallgren KA; Soth S; Grekin P; Woolworth S; Tsui JI
    Addict Sci Clin Pract; 2023 Mar; 18(1):21. PubMed ID: 36991506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State guidance and system changes related to COVID-19: Impact on opioid treatment programs.
    Fuller DB; Gryczynski J; Schwartz RP; Halsted C; Mitchell SG; Whitter M
    J Subst Use Addict Treat; 2024 Mar; 158():209214. PubMed ID: 38042301
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.